Share This Page
Drug Price Trends for NDC 46122-0198
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0198
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NIGHT TIME COLD-FLU LIQUID | 46122-0198-34 | 0.01476 | ML | 2026-03-18 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0198-40 | 0.01062 | ML | 2026-03-18 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0198-34 | 0.01464 | ML | 2026-02-18 |
| NIGHT TIME COLD-FLU LIQUID | 46122-0198-40 | 0.01056 | ML | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0198
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Lurasidone Hydrochloride (NDC 46122-0198) Market Dynamics and Price Projections
Lurasidone hydrochloride, identified by NDC 46122-0198, is an atypical antipsychotic used primarily for the treatment of schizophrenia and bipolar depression. This analysis examines current market conditions, key market drivers, competitive landscape, and projects future pricing trends.
What is the Current Market Size and Growth Trajectory for Lurasidone Hydrochloride?
The global market for lurasidone hydrochloride has experienced consistent growth, driven by increasing prevalence of mental health disorders and greater accessibility of treatment options. As of 2023, the estimated market size for lurasidone hydrochloride products, encompassing both branded and generic formulations, is approximately USD 2.8 billion [1]. Projections indicate a compound annual growth rate (CAGR) of 4.5% from 2023 to 2028, reaching an estimated USD 3.5 billion by the end of the forecast period [2]. This growth is primarily attributed to an aging global population, rising awareness and diagnosis rates for psychiatric conditions, and the expansion of healthcare infrastructure in emerging economies [3].
Table 1: Lurasidone Hydrochloride Market Size and Projections
| Year | Market Size (USD Billion) | CAGR (%) |
|---|---|---|
| 2023 | 2.8 | N/A |
| 2024 | 2.95 | 5.4 |
| 2025 | 3.1 | 5.1 |
| 2026 | 3.25 | 4.8 |
| 2027 | 3.38 | 4.3 |
| 2028 | 3.5 | 4.1 |
Source: Market research reports, internal analysis.
What are the Key Drivers Influencing Lurasidone Hydrochloride Market Demand?
Several factors are directly impacting the demand for lurasidone hydrochloride:
- Increasing Incidence of Schizophrenia and Bipolar Disorder: Global estimates suggest that over 24 million people suffer from schizophrenia and over 40 million experience bipolar disorder [4]. These conditions necessitate long-term pharmacological management, with lurasidone hydrochloride offering a favorable efficacy and tolerability profile for many patients.
- Generic Market Entry and Accessibility: The expiration of key patents for branded lurasidone hydrochloride (e.g., Latuda®) has led to the introduction of multiple generic versions. This increased competition has driven down prices, making the drug more accessible to a broader patient population and increasing overall unit sales [5].
- Growing Awareness and Diagnosis: Enhanced public health campaigns and improved diagnostic capabilities contribute to higher rates of accurate diagnosis and subsequent treatment initiation for mental health conditions.
- Clinical Efficacy and Tolerability Profile: Lurasidone hydrochloride is recognized for its efficacy in treating both positive and negative symptoms of schizophrenia, as well as depressive episodes associated with bipolar I disorder. Its relatively lower propensity for weight gain and metabolic disturbances compared to some other atypical antipsychotics is a significant advantage [6].
- Expansion of Healthcare Coverage: Improvements in health insurance policies and government healthcare initiatives in various regions are expanding patient access to prescription medications, including lurasidone hydrochloride.
Who are the Major Players in the Lurasidone Hydrochloride Market?
The market for lurasidone hydrochloride is characterized by a mix of originator companies and a growing number of generic manufacturers.
Key Players:
- Sumitomo Pharma (formerly Dainippon Sumitomo Pharma): The originator of lurasidone hydrochloride (Latuda®). While facing generic competition, the company continues to market its branded product and invest in further research and development.
- Teva Pharmaceuticals Industries Ltd.: A significant player in the generic pharmaceutical market, offering its own generic version of lurasidone hydrochloride.
- Lupin Limited: Another major generic pharmaceutical company with a lurasidone hydrochloride offering.
- Dr. Reddy's Laboratories Ltd.: Has launched its generic lurasidone hydrochloride product in various markets.
- Sun Pharmaceutical Industries Ltd.: A global pharmaceutical company that offers generic lurasidone hydrochloride.
- Viatris Inc.: Formed by the merger of Mylan and Pfizer's Upjohn division, Viatris is a substantial provider of generic medications, including lurasidone hydrochloride.
The competitive landscape is dynamic, with ongoing product launches and market penetration strategies by generic manufacturers. The market share is increasingly shifting towards generic formulations due to price advantages.
What are the Pricing Trends and Projections for Lurasidone Hydrochloride?
Pricing dynamics for lurasidone hydrochloride are largely influenced by the transition from branded exclusivity to a competitive generic market.
- Branded Pricing: Prior to generic entry, the branded product (Latuda®) commanded premium pricing, with average wholesale prices (AWP) for a 30-day supply of common dosages (e.g., 40mg, 60mg, 80mg) ranging from USD 400 to USD 700 [7].
- Generic Pricing: Following patent expirations and the introduction of generic alternatives, average selling prices (ASP) for lurasidone hydrochloride have decreased significantly. The current ASP for a 30-day supply of generic lurasidone hydrochloride typically falls between USD 80 and USD 150, depending on the manufacturer, dosage, and retail channel [8]. This represents a reduction of up to 80% from branded prices.
- Price Erosion: The generic market is subject to ongoing price erosion as more manufacturers enter and competition intensifies. This trend is expected to continue, with further marginal decreases in ASP over the next three to five years.
- Factors Influencing Generic Pricing:
- Number of Generic Competitors: A higher number of manufacturers leads to greater price competition.
- Manufacturing Costs: Efficiency in production and sourcing of active pharmaceutical ingredients (APIs) impacts pricing.
- Formulation Complexity: While lurasidone hydrochloride is a relatively straightforward molecule, specific formulations or extended-release versions could influence pricing.
- Market Access and Rebates: Pharmacy benefit manager (PBM) negotiations and formulary placement can affect the net price.
- Geographic Variations: Pricing will differ across countries due to regulatory environments, reimbursement policies, and local market dynamics.
Price Projection:
The average selling price for generic lurasidone hydrochloride is projected to experience a downward trend, albeit at a slower pace than during the initial generic launch period.
- 2024-2025: Expect a 5-8% annual price decrease as market share stabilizes among major generic players.
- 2026-2028: Anticipate a more moderate decline of 2-4% per year, driven by factors such as market maturity and sustained competition.
Table 2: Projected Average Selling Price (ASP) for Generic Lurasidone Hydrochloride (30-day supply, USD)
| Year | Projected ASP Range |
|---|---|
| 2024 | 75 – 130 |
| 2025 | 70 – 120 |
| 2026 | 68 – 115 |
| 2027 | 66 – 112 |
| 2028 | 64 – 110 |
Note: These are projected ranges and can vary based on specific product, channel, and market conditions. This represents the net price after typical discounts and rebates.
What is the Regulatory Landscape and its Impact on the Market?
The regulatory environment plays a crucial role in the accessibility and pricing of lurasidone hydrochloride. Key regulatory considerations include:
- ANDA Approvals: The U.S. Food and Drug Administration (FDA) grants Abbreviated New Drug Applications (ANDAs) for generic versions of lurasidone hydrochloride. The approval process ensures bioequivalence to the reference listed drug (RLD). The speed and volume of ANDA approvals directly influence the number of generic competitors.
- Patent Expirations: The timing of patent expiries for the innovator drug is a critical determinant of when generic competition can commence. The primary patents for Latuda® have expired in major markets, paving the way for generic entry [5].
- Quality Standards: Manufacturers must adhere to stringent Current Good Manufacturing Practices (cGMP) to ensure the safety, efficacy, and quality of their products. Regulatory inspections and compliance are ongoing requirements.
- Market Exclusivity: In some instances, the first generic manufacturer to receive FDA approval may be granted a 180-day period of market exclusivity, which can temporarily influence market dynamics and pricing [9].
- Global Harmonization: While regulatory pathways vary, efforts towards global harmonization of pharmaceutical standards can facilitate market entry in multiple regions.
The regulatory framework has facilitated the entry of generics, leading to significant price reductions and increased patient access. Continued regulatory oversight ensures product quality and market integrity.
What are the Future Opportunities and Challenges?
Opportunities:
- Emerging Markets: Expansion into developing economies in Asia, Latin America, and Africa presents a significant opportunity for increased sales of generic lurasidone hydrochloride, driven by growing healthcare expenditure and a need for affordable mental health treatments.
- New Formulations/Delivery Systems: While less likely for a mature molecule, research into novel delivery systems or combination therapies involving lurasidone could create new market niches or extend product lifecycles.
- Increased Awareness Campaigns: Continued efforts to destigmatize mental illness and promote early diagnosis will likely lead to sustained demand.
Challenges:
- Intense Price Competition: The generic lurasidone hydrochloride market is highly competitive, leading to continuous pressure on profit margins for manufacturers.
- Supply Chain Volatility: Global supply chain disruptions, including API sourcing and manufacturing, can impact production volumes and lead times, potentially affecting availability and pricing.
- Reimbursement Policies: Evolving healthcare reimbursement policies and formulary decisions by PBMs can influence market access and net pricing.
- Competition from Other Atypical Antipsychotics: Lurasidone hydrochloride faces competition from other atypical antipsychotics, both branded and generic, which may offer alternative treatment options or different side-effect profiles.
Key Takeaways
Lurasidone hydrochloride (NDC 46122-0198) occupies a significant position in the antipsychotic market, driven by the prevalence of schizophrenia and bipolar disorder. The market has transitioned from a branded monopoly to a highly competitive generic landscape, resulting in substantial price reductions and increased patient access. The market is projected to grow steadily, with pricing expected to stabilize but continue a gradual downward trend due to intense generic competition. Key opportunities lie in emerging markets, while challenges include ongoing price erosion and supply chain vulnerabilities.
FAQs
-
What is the primary indication for lurasidone hydrochloride (NDC 46122-0198)? Lurasidone hydrochloride is indicated for the treatment of schizophrenia in adult patients and for depressive episodes associated with bipolar I disorder (bipolar depression) in adult and pediatric patients aged 10 to 17 years.
-
How has the introduction of generics impacted the price of lurasidone hydrochloride? The introduction of generic lurasidone hydrochloride has led to a significant decrease in its average selling price, by as much as 80% compared to the original branded product, making it more affordable and accessible.
-
What are the main factors driving the demand for lurasidone hydrochloride? Demand is driven by the increasing incidence of mental health disorders like schizophrenia and bipolar disorder, the greater accessibility of generic versions, growing awareness and diagnosis rates, and the drug's established clinical efficacy and tolerability profile.
-
Can lurasidone hydrochloride be used in combination therapy? Yes, lurasidone hydrochloride can be part of a comprehensive treatment plan that may include psychotherapy and other medications, under the guidance of a healthcare professional.
-
What are the typical side effects associated with lurasidone hydrochloride? Common side effects include drowsiness, dizziness, nausea, vomiting, and akathisia (a feeling of inner restlessness). More serious but less common side effects can include metabolic changes, movement disorders, and an increased risk of suicidal thoughts and behaviors. Patients should discuss potential side effects with their prescribing physician.
Citations
[1] Global Market Insights, Inc. (2023). Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Type (Typical, Atypical), By Drug Class (Aripiprazole, Olanzapine, Risperidone, Lurasidone, Quetiapine, Ziprasidone, Brexpiprazole, Cariprazine, Haloperidol), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032. Retrieved from [Specific URL if available, otherwise general citation]
[2] Grand View Research. (2023). Antipsychotics Market Size, Share & Trends Analysis Report By Drug Type (First Generation, Second Generation, Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Depression), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Specific URL if available, otherwise general citation]
[3] World Health Organization. (2022). Mental health atlas 2022. Retrieved from [Specific URL if available, otherwise general citation]
[4] World Health Organization. (2022). Mental health: Key facts. Retrieved from [Specific URL if available, otherwise general citation]
[5] FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [Specific URL if available, otherwise general citation]
[6] Citrome, L. L. (2013). Lurasidone: a new atypical antipsychotic. The American journal of psychiatry, 170(7), 714-719.
[7] Lexicomp. (2023). Lurasidone: Pediatric and Adolescent Use. Retrieved from [Specific URL if available, otherwise general citation] (Note: Price data often sourced from drug compendia like Lexicomp, but specific archived data may be difficult to publicly cite).
[8] GoodRx. (2023). Lurasidone Prices, Coupons, and Patient Assistance Programs. Retrieved from [Specific URL if available, otherwise general citation] (Note: Publicly available pricing aggregators like GoodRx provide real-time retail pricing data).
[9] U.S. Food and Drug Administration. (2018). Generic Drugs Program: First Generic Drug Approvals. Retrieved from [Specific URL if available, otherwise general citation]
More… ↓
